BACKGROUNDWhile considered simple and effective, crystalloid antegrade cardioplegia solutions have had few prospective multicentre comparison trials.METHODSA commercial intracellular-type histidine-tryptophan-ketoglutarate (HTK) cardioplegia solution (Custodiol HTK; Köhler Chemie GmbH, Germany) designed for 4 h of protection after a single administration was compared with a standard extracellular multidose product (Plegisol [PL]; Hospira Inc, USA) in an open-label, randomized, prospective seven-institution trial. A total of 136 isolated coronary bypass patients were randomly assigned into two groups and stratified by ejection fraction into categories of 40% or greater (n=118) and 20% to 39% (n=18).RESULTSThe mean age of the study cohort was 62 years, of which 94% were men. Seventy per cent of patients had Canadian Cardiovascular Society class III angina and 75% had three-vessel disease anatomy. Cross-clamp times were nearly identical for patients in both cardioplegia groups; however, defibrillation was needed less often for patients who were treated with HTK (64% versus 91%, P<0.01). Hospital and intensive care unit stays, creatine kinase isoenzyme MB curves, cardiac outputs, inotrope levels, and deaths or serious adverse events (PL=13, HTK=14) were very similar between groups. Logistic regression showed that myocardial infarction or possible treatment-related adverse events were associated with high cardiac troponin I (cTn-I) levels 6 h after the procedure (P=0.001), and HTK treatment (OR 3.5, P=0.01). The primary study end point (6 h post-ischemia cTn-I) favoured PL (16.7±13.2 μg/L versus 20.3±13.5 μg/L, P=0.01). Patients who underwent circumflex grafting had higher cTn-I levels with HTK (P<0.001) and 48% required reinfusions due to cardiac warming. Longer intervals between doses correlated with high cTn-I levels (P=0.02). HTK provided prolonged protection with low cTn-I release (10 μg/L or less), although this occurred less frequently than with PL (17 versus 27 patients, P=0.06).CONCLUSIONSHTK caused more structural protein release and adverse events than PL, even when reinfusion was implemented.

01 Jan 2006·Journal of Investigative SurgeryQ4 · MEDICINE

Impact of Acute Myocardial Edema on Left Ventricular Function

Q4 · MEDICINE

Article

Author: Glen A. Laine ; Steven J. Allen ; Uwe M. Fischer ; Charles S. Cox ; Randolph H. Stewart

Studies of the impact of myocardial edema on left ventricular (LV) systolic function show conflicting results. We sought to evaluate the impact of increased myocardial water content (MWC) on LV systolic and diastolic function. Anesthetized dogs (n = 12) were instrumented with myocardial ultrasonic crystals and an LV micromanometer. Systolic function was measured by preload recruitable stroke work (PRSW) and dP/dt(max). Diastolic function was measured by -dP/dt(max) and the isovolumic relaxation constant tau (t). Myocardial water content (MWC) was determined using microgravimetry. In six dogs (coronary sinus hypertension, CSH group) we produced myocardial edema by inflating a coronary sinus balloon for 2 h (30-40 mm Hg). In six other dogs (Plegisol, PLEG group) cardiopulmonary bypass (CPB) was initiated (12.3 +/- 0.8 min), the aorta was cross-clamped (117 +/- 19 s), and 700 mL 4 degrees C crystalloid, hyperkalemic cardioplegic solution (Plegisol) was administered into the aortic root (62 +/- 4 mm Hg). After declamping and reperfusion (7.2 +/- 1.0 min), the dogs were separated from CPB. Myocardial function parameters and MWC were measured for 2 h after edema generation. In the CSH group, MWC significantly increased from 75.9 +/- 0.3% to 77.6 +/- 0.3% (p < .05). In the PLEG group, MWC increased from 75.8 +/- 0.3% to 77.7 +/- 0.3% (p < .05). PRSW and dP/dt(max) did not decrease in either group. Diastolic parameters did not change significantly. We conclude that acute myocardial edema without myocardial injury does not impair LV function.

01 Jan 2006·The Annals of Thoracic SurgeryQ2 · MEDICINE

Role of the Sarcolemmal Adenosine Triphosphate–Sensitive Potassium Channel in Hyperkalemic Cardioplegia-Induced Myocyte Swelling and Reduced Contractility

Q2 · MEDICINE

Article

Author: Jennifer S. Lawton ; Thomas P. Flagg ; Ralph J. Damiano ; Ashraf S. Al-Dadah ; Gregory D. Byrd ; Jefferson Gomes ; Colin G. Nichols ; Sandip M. Prasad

BACKGROUNDHyperkalemic cardioplegia (Plegisol) has been shown to result in myocyte swelling and reduced contractility. We have demonstrated the elimination of these detrimental effects by the addition of an adenosine triphosphate-sensitive K+ (KATP) channel opener. To examine whether the mitochondrial or sarcolemmal KATP channel might be involved, volume and contractility in isolated myocytes from wild-type mice and mice lacking the sarcolemmal KATP channel (Kir6.2-/-) were evaluated.METHODSMyocytes were perfused for 20 minutes each with control 37 degrees C Tyrode's solution, test solution, and then control solution. Test solutions were (n = 10 per group) either 9 degrees C Plegisol or 9 degrees C Plegisol with 100 micromol/L of diazoxide, a putative mitochondrial-specific KATP channel opener. Cell volume and contractility were measured by digital video microscopy at baseline and during the test solution and reexposure periods.RESULTSMyocytes from wild-type mice, perfused with 9 degrees C Plegisol, demonstrated significant cell swelling (11.2% +/- 0.4%; p < 0.01) and diminished contractility (32.5% +/- 9.6% reduction in percent shortening, 47.2% +/- 10.1% reduction in peak velocity of shortening, and 52.0% +/- 8.8% reduction in peak velocity of relengthening; p < 0.05) versus baseline. Cell swelling and diminished contractility were significantly reduced by the addition of diazoxide. In Kir6.2-/- myocytes, Plegisol caused a greatly reduced level of cell swelling (3.2% +/- 0.1%; p < 0.01), and this was unaffected by diazoxide. Contractility was unchanged in Kir6.2-/- myocytes after Plegisol.CONCLUSIONSThe sarcolemmal KATP channel appears necessary for exaggerated cell swelling and reduced contractility to occur after hyperkalemic cardioplegia in mouse myocytes.

100 Deals associated with Calcium chloride/Magnesium chloride/Potassium chloride/Sodium chloride

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nutritional and Metabolic Diseases	US	Hospira, Inc.	26 Feb 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Calcium chloride/Magnesium chloride/Potassium chloride/Sodium chloride

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation